Express . . . Sanofi has partnered nearly $1 billion to build a new combination of NK cells/CD38 antibodies against cancer.

▎ the editor of the content team of YaoMing Kant today, kiadis Pharma, which is committed to the development of innovative natural killer (NK) cell therapy, announced that it has reached a research and development license agreement with Sanofi company, granting Sanofi the exclusive R & D license for kiadis's previously undisclosed k-nk004 project.k-nk004 is a NK cell therapy using gene engineering knockout to eliminate CD38 expression.Sanofi plans to combine it with sarclisa, a CD38 antibody developed by the company, to treat patients with multiple myeloma.in addition, Sanofi also obtained the exclusive right to develop two undisclosed preclinical projects using kiadis's k-nk platform.natural killer cells are the first line of defense against cancer and infection.antibodies cooperate with NK cells to kill tumor cells. This process is called antibody dependent cell-mediated cytotoxicity (ADCC).however, since NK cells express CD38 antigen, the use of anti-CD38 antibodies (such as sarclisa) in the treatment of multiple myeloma will deplete the NK cells of the patients themselves.kiadis's k-nk004 therapy can prevent the expression of CD38 through genetic engineering of NK cells, so it is resistant to CD38 targeted therapy.adjuvant infusion of CD38 knockout NK cells will re-establish the natural synergy between NK cells and antibodies, kill tumor cells and optimize the efficacy. Br / > < 1.5 billion yuan of the company's R & D (kiadis / >) will be paid as part of the company's clinical pipeline agreement (up to US $1.75 billion) and the company's website has the right to pay up to US $1.75 billion.kiadis will also receive a share of the sales of the approved products developed under this agreement.it is worth mentioning that this strategy of removing specific antigens from healthy cells through genetic engineering and protecting them from cancer targeted therapy is also being used by other companies.yesterday, VOR biopharma, which uses a similar strategy to develop cancer therapies, announced the completion of a $110 million round of B financing.the core technology comes from Dr. Siddhartha Mukherjee, the author of the best-selling book "the king of diseases: a biography of cancer.".References: [1] kiadis licenses previously undisclosed pre clinical k-nk-cell programs to Sanofi, with total potential deal value of 875 million, plus royalties. Retrieved July 8, 2020, from note: This paper aims to introduce the research progress of medical and health, not to recommend treatment options.if you need guidance on treatment plan, please go to a regular hospital.